BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-956@pharmaconomics
DTSTAMP:20260707T021626Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:LXRX Phase 3 — sotagliflozin (estimated date)
DESCRIPTION:Phase 3 trial results for sotagliflozin in hypertrophic cardiomyopathy (HCM) are due ~ Mar 31\, 2027. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1062822/000119312526029514/d61153d8k.htm\n\nTrack it: https://pharmaconomics.com/e/956
URL:https://pharmaconomics.com/e/956
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:LXRX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR